Skip to main content
Premium Trial:

Request an Annual Quote

Roche's Flatiron Health, Foundation Medicine, Genentech Launch Clinico-Genomic Lung Cancer Study

NEW YORK – Roche companies Flatiron Health, Foundation Medicine, and Genentech announced on Monday the launch of their Prospective Clinico-Genomic (PGC) study, a collaborative effort meant to streamline clinical trials in advanced lung cancer and to identify genomic features to predict treatment response or resistance.

The PGC study is funded and sponsored by Genentech and currently involves 14 academic and community oncology centers, with additional research sites planned. The feasibility study will pilot Flatiron Health's technology platform to prospectively collect real-world data from the roughly 1,000 patients enrolled. Researchers will then link this real-world data with genomic information gleaned from serial liquid biopsies using Foundation Medicine's assay designed to assess genomic changes over the course of a patient's treatment.

The real-world data and liquid biopsy results will be combined with clinical, imaging, and outcomes data, ultimately creating a comprehensive platform to accelerate lung cancer research and simplify and streamline the way that clinical research is performed, the partners said. The PGC study officially launched in December 2019, and an update on its progress will be shared through a Trials in Progress presentation during the American Society of Clinical Oncology's 2020 Virtual Annual Meeting.

"Using new platforms to accelerate the development and delivery of the best possible medicines for every type of patient is central to our vision for personalized healthcare," Mark Lee, Genentech's head of personalized healthcare and product development, said in a statement. "The PCG Study represents an important step toward the next iteration of the clinical research ecosystem, opening up opportunities to extend clinical trials into the real-world setting to more investigators and more patients than ever before."

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.